Article

SABCS: Debu Tripathy Discusses PI3 Kinase Inhibitors in Breast Cancer

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving the PI3 kinase inhibitor pictilisib showed interesting results.

Debu Tripathy, editor-in-chief of CURE magazine, reports from the San Antonio Breast Breast Cancer Symposium where a study involving a PI3 kinase inhibitor showed interesting results.

While the clinical trial involving the investigational agent pictilisib with an aromatase inhibitor had only modest results, interest in this type of targeted therapy remains, particularly in different stages of the disease and in combination with other drugs.

You can read more on the study at "Early Phase Study Finds PI3K Inhibitor Pictilisib Helps a Subset of Advanced Breast Cancer Patients."

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content